Clinical Trial

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Study acronym: RE-UNITE PN
Recruiting
View on ClinicalTrials.gov →
Summary
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-05-16; most recent amendment 2026-05-28.
Status change: Not Yet Recruiting → Recruiting 2025-08-13
Trial Details
NCT Number NCT06988618
Lead Sponsor Galderma R&D
Conditions Prurigo Nodularis
Enrollment 600 participants
Start Date 2025-08-11
Primary Completion 2027-11-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-01